3H-咪唑并[1,2-a]嘧啶-7-酮 | 55662-33-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 3H-咪唑并[1,2-a]嘧啶-7-酮
• 英文名称: imidazolo<1,2-a>pyrimidine-7(8H)-one
• 英文别名: imidazo<1,2-a>pyrimidin-7(8H)-one；imidazo[1,2-a]pyrimidin-7-(8H)-one；8H-imidazo[1,2-a]pyrimidin-7-one；Imidazo[1,2-a]pyrimidin-7(8h)-one；8H-imidazo[1,2-a]pyrimidin-7-one
• CAS: 55662-33-4
• 化学式: C₆H₅N₃O
• 分子量: 135.125
• InChiKey: MMTJBYQDUNMHSX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,5'-脱水尿苷 在 sodium hydroxide 、 二正丁基氧化锡 、 三乙胺 、 间氯过氧苯甲酸 作用下， 以 乙醇 、 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 反应 52.17h， 生成 3H-咪唑并[1,2-a]嘧啶-7-酮
  参考文献：
  名称：

  Minamoto, Katsumaro; Azuma, Kishiko; Tanaka, Toshihiro, Journal of the Chemical Society. Perkin transactions I, 1988, p. 2955 - 2962

  摘要：

  DOI：

文献信息

• 1-(Alkyl), 1-((heteroaryl)alkyl) and 1-((aryl)alkyl)-7-pyridin-4-ylimidazo(1,2a)pyrimidin-5(1H)-one derivatives
  申请人：SANOFI-SYNTHELABO

  公开号：EP1184384A1

  公开（公告）日：2002-03-06

  The invention relates to a imidazo[1,2-a]pyrimidone derivative represented by formula (I) or a salt thereof: wherein: X represents a bond, a double bond, a triple bond, a methylene group optionally substituted by one or two groups selected from a C1-6 alkyl group, a hydroxy group and a C1-4 alcoxy group; a carbonyl group, an oxygen atom, a sulfur atom, a sulfonyl group, a sulfoxide group or a nitrogen atom being optionally substituted by a C1-6 alkyl group; R1 represents a 2, 3 or 4-pyridyl group optionally substituted by a C1-4 alkyl group, C1-4 alkoxy group or a halogen atom; R2 represents a C1-6 alkyl group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring, the benzyl group and the rings being optionally substituted by 1 to 3 substituents selected from a C1-6 alkyl group, a halogen atom, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a hydroxyl group, a C1-4 alkoxy group, a nitro, a cyano, an amino, a C1-6 monoalkylamino group or a C2-10 dialkylamino group; and n represents 0 to 3. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β.

  该发明涉及一种由式（I）表示的咪唑并[1,2-a]嘧啶酮衍生物或其盐：其中：X代表键，双键，三键，一个亚甲基基团，该基团可选择性地由C1-6烷基基团，羟基和C1-4醇氧基团中的一个或两个基团取代；一个羰基，氧原子，硫原子，磺酰基，亚砜基或氮原子，该基团可选择性地由C1-6烷基基团取代；R1代表一个2，3或4-吡啶基团，该基团可选择性地由C1-4烷基基团，C1-4烷氧基团或卤原子取代；R2代表一个C1-6烷基基团，一个C1-2全氟烷基基团，一个C1-3卤代烷基基团，一个苄基团，一个苯环，一个吡啶环，一个吲哚环，一个吡咯环，一个噻吩环，一个呋喃环或一个咪唑环，苄基团和环可选择性地由1至3个取代基团取代，所述取代基团选自C1-6烷基基团，卤原子，C1-2全氟烷基基团，C1-3卤代烷基基团，羟基，C1-4烷氧基团，硝基，氰基，氨基，C1-6单烷基氨基团或C2-10二烷基氨基团；n代表0至3。该发明还涉及一种药物，其包括作为预防和/或治疗由GSK3β异常活性引起的神经退行性疾病的活性成分的上述衍生物或其盐。
• [EN] NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER<br/>[FR] NOUVEAUX COMPOSÉS DESTINÉS AU TRAITEMENT DU CANCER
  申请人：BAYER PHARMA AG

  公开号：WO2014198594A1

  公开（公告）日：2014-12-18

  The present invention relates to novel compounds showing an inhibitory effect on Mps-1 kinase, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

  本发明涉及一种对Mps-1激酶具有抑制作用的新化合物，涉及制备该化合物的方法，包括该化合物的药物组合物和组合物，以及用于制造治疗或预防疾病的药物组合物的使用，以及在制备该化合物中有用的中间体化合物。
• Duplex DNA and DNA–RNA Hybrids with Parallel Strand Orientation: 2′-Deoxy-2′-fluoroisocytidine, 2′-Deoxy-2′-fluoroisoguanosine, and Canonical Nucleosides with 2′-Fluoro Substituents Cause Unexpected Changes on the Double Helix Stability
  作者：Sachin A. Ingale、Peter Leonard、Quang Nhat Tran、Frank Seela

  DOI：10.1021/acs.joc.5b00040

  日期：2015.3.20

  hybrids with antiparallel strand orientation. Unexpected strong stability changes are observed for oligonucleotide duplexes with parallel chains. While fluorinated oligonucleotides form moderately stable parallel stranded duplexes with complementary DNA, they do not form stable hybrids with RNA. Furthermore, oligoribonucleotide duplexes with parallel strand orientation are extremely unstable. It is anticipated

  具有平行或反平行链取向的寡核苷酸，并带有2'氟化的2'-脱氧核糖核苷和规范的核碱基或2'-deoxy-2'-氟异胞苷（F iC d，1c）和2'-deoxy-2'-氟异鸟苷（F iG d），3c）被合成。为此，制备核苷1c和3c以及亚磷酰胺结构单元19和23，并将其用于固相寡核苷酸合成中。出乎意料的是，F iC d在寡核苷酸脱保护过程中不稳定（55°C，NH 3水溶液））并转化为环核苷（14）。当寡核苷酸在温和的条件下（氨水-乙醇，室温）脱保护时，可避免副产物的形成。含有2'-氟取代基的寡核苷酸（F iC d，F iG d和含氟的典范2'-脱氧核糖核苷）可稳定具有反平行链取向的双链DNA，RNA和DNA-RNA杂种。对于具有平行链的寡核苷酸双链体，观察到了意外的强稳定性变化。氟化寡核苷酸与互补DNA形成中等稳定的平行链双链体，但与RNA却不形成稳定的杂交体。此外，具有平行链取向的寡核糖核苷
• 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives
  申请人：SANOFI-SYNTHELABO

  公开号：EP1340759A1

  公开（公告）日：2003-09-03

  The invention relates to a imidazo[1,2-a]pyrimidone derivative represented by formula (I) or a salt thereof: Wherein: X represents a bond, an ethenylene group, an ethynylene group, a methylene group optionally substituted; a carbonyl group, an oxygen atom, a sulfur atom, a sulfonyl group, a sulfoxide group or a nitrogen atom being optionally substituted; R1 represents a 2, 4 or 5-pyrimidinyl optionally substituted; R2 represents a C1-6 alkyl group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a benzyl group, a phenyl ring, a naphthyl ring, 5,6,7,8-tetrahydronaphthyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring, the benzyl group and the rings being optionally substituted; and n represents 0 to 3. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer disease.

  本发明涉及一种由式(I)表示的咪唑并[1,2-a]嘧啶酮衍生物或其盐： 其中，X代表一个键，一个乙烯基，一个乙炔基，一个甲基基团可选择性地被取代的羰基，一个氧原子，一个硫原子，一个磺酰基，一个亚磺酸基或一个氮原子，R1代表一个选择性取代的2、4或5-嘧啶基，R2代表一个C1-6烷基，一个C1-2全氟烷基，一个C1-3卤代烷基，一个苄基，一个苯环，一个萘环，5,6,7,8-四氢萘环，一个吡啶环，一个吲哚环，一个吡咯环，一个噻吩环，一个呋喃环或一个咪唑环，其中苄基和环可选择性地被取代，n代表0到3。 本发明还涉及一种药物，其包含所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β异常活动引起的神经退行性疾病，例如阿尔茨海默病。
• Facile Unmasking of Ethenylated Isocytosines via Diacetoxylation with Load Tetraacetate.
  作者：Magoichi SAKO、Reiko TOTANI、Kosaku HIROTA、Yoshifumi MAKI

  DOI：10.1248/cpb.40.235

  日期：——

  Treatment of ethenylated isocytosines, imidazolo[1, 2-α]pyrimidine-5(1H)-one (2) and -7(8H)one (3), with lead tetraacetate (LTA) in glacial acetic acid followed by alkaline hydrolysis resulted in the smooth removal of the ethenyl group to give isocytosine (1) in high yields. The unmasking of 2 by LTA to 1 was compared with the results using iodosylbenzone diacetate and N-bromosuccinimide.

  用四乙酸铅 (LTA) 在冰醋酸中处理乙烯基化异胞嘧啶、咪唑并[1, 2-α]嘧啶-5(1H)-一 (2) 和 -7(8H)一 (3)，然后进行碱性水解，得到顺利去除乙烯基，以高产率得到异胞嘧啶 (1)。将 LTA 对 2 的解密结果与使用碘酰苯二乙酸酯和 N-溴代琥珀酰亚胺的结果进行了比较。